drugset / Trial / NCT01733589
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Phase 1/2
Completed
73 enrolled
Zhejiang Cancer Hospital
Chinese Academy of Medical Sciences · collabFudan University · collabFujian Cancer Hospital · collabJiangsu Cancer Institute & Hospital · collabPeking University Cancer Hospital & Institute · collabShandong Cancer Hospital and Institute · collabThe First People's Hospital of Lianyungang · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas. Preclinical models have shown that Endostar may transiently "normalize" the tumor vasculature to make it more efficient for oxygen delivery, thereby providing a window of opportunity for enhanced sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT regimen in patients with unresectable stage III NSCLC.
Timeline
- Start
- 2012-11
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 50 mg/m2 | Intravenous |